ArticleBioinformatics (Oxford, England)2026
Multi-objective-conditioned-return-blocks decision transformer: a novel approach for multi-objective de novo drug design.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
motivationDesigning novel molecules that simultaneously satisfy several, often conflicting, properties is a long-standing challenge in drug design. While recent deep learning advances optimize single targets effectively, navigating the tradeoffs required for multiple objectives remains a difficult problem.
resultsWe introduce the Multi-Objective-Conditioned-Return-Blocks Decision Transformer (M-GoRT), a novel architecture for multi-target de-novo drug design incorporating return-to-go blocks conditioned on goal embeddings. Trained without exploration, reward weighting or online fine-tuning, M-GoRT efficiently optimizes for multiple targets. M-GoRT achieves competitive multi-objective success rates against state-of-the-art baselines while maintaining superior structural diversity and novelty, even in high-dimensional tasks incorporating biological targets (DRD2, JNK3). In these high-dimensional tasks, M-GoRT maintains superior structural diversity and novelty establishing it as a practical tool for multi-property molecular generation. AVAILABILITY AND IMPLEMENTATION: M-GoRT and the data used are freely available as an open-source software under the MIT license at GitHub https://github.com/eyalmazuz/MolGen/tree/GCRB-DT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.